Safety and efficacy of an extended‐release peptide YY analogue for obesity: A randomized, placebo‐controlled, phase 1 trial

Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy

(2020) Bernard Khoo et al.   JOURNAL OF ENDOCRINOLOGY

Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom

(2020) Mark Hamer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

(2020) Karine Clément et al.   Lancet Diabetes & Endocrinology

A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates

(2019) Shamina M. Rangwala et al.   Cell Metabolism

Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study

(2019) Preeshila Behary et al.   DIABETES CARE

The Science of Obesity Management: An Endocrine Society Scientific Statement

(2018) George A Bray et al.   ENDOCRINE REVIEWS

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

(2018) Philip Ambery et al.   LANCET

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

(2018) Patrick M O'Neil et al.   LANCET

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis

(2017) Chenhan Ma et al.   BMJ-British Medical Journal

Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis

(2017) Chenhan Ma et al.   BMJ-British Medical Journal

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events

(2016) Rohan Khera et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

How common is hypoglycemia after gastric bypass?

(2016) Allison B. Goldfine et al.   Obesity

Combination of Peptide YY3–36with GLP-17–36 amideCauses an Increase in First-Phase Insulin Secretion after IV Glucose

(2014) Tricia M. Tan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery

(2013) L. Sjöström   JOURNAL OF INTERNAL MEDICINE

A Review of Adult Mortality Due to 2009 Pandemic (H1N1) Influenza A in California

(2011) Janice K. Louie et al.   PLoS One

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET